Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00026312 · OUTCOME

Number of Courses of Therapy Delivered

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma · Source last updated 2026-03-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
courses per patient
Interval / dispersion
Full Range
Time frame
Courses 1-6

What was measured

Number of courses of therapy delivered for patients randomized to RA + Immunotherapy vs. patients non-randomly assigned to RA + Immunotherapy, excluding patients with persistent disease.

Analysis population: Eligible patients assigned to Regimen B, excluding patients with persistent disease.

Groups in this outcome

Regimen B

Regimen B- RA + Immunotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Regimen B1291

Reported measurements

Randomized to Regimen B - RA + Immunotherapy
Values in courses per patient · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Regimen B6Not reported06Not reported
Non-randomly assigned after halting randomization
Values in courses per patient · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Regimen B6Not reported06Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    group Description
    The number of courses of therapy delivered or patients randomized to Regimen B - RA + Immunotherapy and non-randomly assigned to Regimen B after halting of randomization, excluding patients with persistent disease, were compared using the Wilcoxon rank-sum test.
    group Ids
    1. OG000
    non Inferiority Type
    SUPERIORITY_OR_OTHER_LEGACY
    p Value
    0.0262
    param Type
    Mean Difference (Net)
    param Value
    0
    statistical Method
    Wilcoxon (Mann-Whitney)
Complete source fields
analyses
  1. ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    group Description
    The number of courses of therapy delivered or patients randomized to Regimen B - RA + Immunotherapy and non-randomly assigned to Regimen B after halting of randomization, excluding patients with persistent disease, were compared using the Wilcoxon rank-sum test.
    group Ids
    1. OG000
    non Inferiority Type
    SUPERIORITY_OR_OTHER_LEGACY
    p Value
    0.0262
    param Type
    Mean Difference (Net)
    param Value
    0
    statistical Method
    Wilcoxon (Mann-Whitney)
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        6
        value
        6
    title
    Randomized to Regimen B - RA + Immunotherapy
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        6
        value
        6
    title
    Non-randomly assigned after halting randomization
denoms
  1. counts
    1. group Id
      OG000
      value
      1291
    units
    Participants
description
Number of courses of therapy delivered for patients randomized to RA + Immunotherapy vs. patients non-randomly assigned to RA + Immunotherapy, excluding patients with persistent disease.
dispersion Type
Full Range
groups
  1. description
    Regimen B- RA + Immunotherapy
    id
    OG000
    title
    Regimen B
param Type
MEDIAN
population Description
Eligible patients assigned to Regimen B, excluding patients with persistent disease.
reporting Status
POSTED
time Frame
Courses 1-6
title
Number of Courses of Therapy Delivered
type
SECONDARY
unit Of Measure
courses per patient

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice